Psychological Distress and Use of Psychotropic Drugs Among University Students—the SHoT Study, Norway

Ivana Bojanić 1, Erik R. Sund 1,2,3, Ottar Bjerkeset 4,5, Børge Sivertsen 4,5,6 and Hege Sletvold 1*

1 Faculty of Nursing and Health Sciences, Nord University, Levanger Municipality, Norway, 2 Department of Public Health and Nursing, Faculty of Medicine and Health Science, HUNT Research Centre, Norwegian University of Science and Technology, Levanger Municipality, Norway, 3 Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger Municipality, Norway, 4 Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway, 5 Department of Health Promotion, Norwegian Institute of Public Health, Bergen, Norway, 6 Department of Research & Innovation, Helse Fonna HF, Haugesund, Norway

Background: Students pursuing higher education are struggling with psychological distress, which in turn may negatively affect their academic self-efficacy and study progress. Although psychotropic drug use is widespread and increasing, patterns of psychotropic drug use among students are not well-known.

Aim: To describe prevalence and gender differences in psychotropic drug use among Norwegian students in higher education, and to examine associations with level of psychological distress.

Methods: The study is based on data from the Norwegian Student’s Health and Well-being Study (SHoT), 2018, a national survey including all fulltime students aged 18–35 years in higher education. Our sample included 49,836 students, 69% females. Use of psychotropic drugs and psychological distress (The Hopkins Symptoms Checklist [HSCL-25]) were self-reported. Generalised linear models were used to assess associations between psychological distress and psychotropic drug use.

Results: Psychotropic drug use was more frequent among female than male students: 4 vs. 2% daily antidepressants usage; 5 vs. 3% last month use of anxiolytics/tranquilisers; and 8 vs. 5% last month use of hypnotics. In contrast, male students reported use of performance enhancing drugs more often than females (7 vs. 5%). Adjusted associations between high level of psychological distress (HSCL-25 ≥ 2.0) and use of psychotropics, showed an about 2-fold increased relative risk, largely consequent across drug classes and genders.

Conclusion: Prevalence and gender patterns of intake of the most common psychotropic drug classes among Norwegian students are comparable to previous studies. Unexpectedly, among students with moderate to severe psychological distress, the patterns of psychotropic drug use were more or less identical between genders.

Keywords: students, mental health, psychological distress, psychotropics, antidepressants, hypnotics, anxiolytics, gender differences
INTRODUCTION

Psychological distress is highly prevalent among university and college students worldwide (1) and often has negative effects on several domains of students’ life (2, 3). Psychological distress is defined as emotional suffering characterised by symptoms like depression (e.g., loss of interest, sadness, hopelessness), anxiety (e.g., restlessness, feeling tense) and functional or somatic symptoms (e.g., headache, insomnia, poor appetite, sexual dysfunction, and lack of energy) (4). A recent literature review found that psychological distress was more prevalent and severe among university students compared to their non-studying age-matched peers in the general population (5). Furthermore, psychological distress among students is strongly associated with lower academic self-efficacy and reduced study progress (6), and increased risk of suicidal thoughts and behaviours (7). Thus, preventive interventions, early detection, and optimal treatment of mental illness among students, as well as general improvement of students’ mental health, have become urgent matters.

Both non-pharmacological interventions and psychotropic drugs are cornerstones in the treatment of mental illnesses, and women are more frequent users of both mental healthcare services and these drugs, compared to men (8, 9). A psychotropic drug can be defined as any drug affecting the mind, emotions and behaviour, e.g., stimulants, antidepressants, antipsychotics, anxiolytics, and hypnotics. Parallel to the striking increase in psychological distress in adolescents and young adults (10, 11), the use of psychotropic drugs among children and adolescents has increased in many countries in the last decade (12–16). The same trends have been observed in young adults. According to the Norwegian Prescription Database (NorPD), the 1-year prevalence of psychotropic drug use has increased by about 29% in the last decade among 20–24 year-olds, to 14% in females and 9% in males, in 2019 (17). A case study from Australia confirmed an increasing trend in psychotropic drug prescribing to patients aged 16–24 year with mental disorders from 2009 to 2014, with higher prescription levels in women compared to men (18). Similarly, mental distress among Norwegian female medical students increased from 1993 to 2015, paralleled with a significant increase in mental health help-seeking (19).

Studies investigating psychotropic drug use among students in relation to psychological distress are limited. A study of 21,771 students at a US university, reported increased prevalence of past-year medical use of stimulants (from 1.9 to 4.7%), sedatives/anxiolytics (from 2.9 to 4.3%), and hypnotics (from 2.9 to 3.2%), in the 10-year period from 2003 to 2013 (20). Further, a cross-sectional national study among nearly 11,000 French medical students reported that 12% of students received psychiatric or psychological treatment, while 5.7% used anxiolytics regularly, 2.8% used antidepressants, and 2.1% were hypnotic medication consumers (21). Despite an increasing trend in help-seeking and use of psychotropics among young adults, studies have reported undertreatment of mental health disorders among students (3, 22).

Non-medical use, defined as use without a prescription or use outside the indication of the medication (23), and misuse or illicit use of psychotropic drugs among students is well-documented (24–28). A meta-analysis reported an overall rate of stimulant medication misuse among college students of 17%, more frequent among men compared to women (24). Motives for prescription drug misuse among students include personal performance enhancement in academic or sport outcomes, mental health reasons including ability to sleep or to reduce anxiety, or manage pre-existing illnesses (29). Additionally, the use of stimulants increases with stress (30) and difficulties in academic achievement (31). Moreover, the trends of increased use of prescribed psychotropics among students parallel the increased non-medical use of the same psychotropics (20), highlighting the importance of monitoring prevalence of psychotropic drug use among students. The correct use of psychotropics to enhance mental health of students is of great importance, in addition to ensuring patient safety in this population.

Usually, young adults become fully responsible for their medication management for the first time in life as they become college or university students. Although the study years represent a free and liberating period in life for many young adults, a large portion of students experience student life as mentally stressful and demanding and report high levels of psychological distress (5, 11). Previous research demonstrate that psychological distress affects students worldwide (1), recognising this as an important public health issue. However, studies based on large, nationwide samples including students across all faculties and universities that allow investigation of psychological distress in relation to the use of psychotropic drugs are still scarce. The SHoT study is a national health and well-being survey among Norwegian university students, and was conducted in 2010, 2014, and 2018 (32).

The aim of this study was to study prevalence and gender differences of psychotropic drug use among Norwegian university students based on SHoT 2018 data, and to examine associations with psychological distress symptom load.

MATERIALS AND METHODS

Study Sample and Setting

The SHoT study is a national student health survey for higher education conducted every 4 years since 2010. The size and scope of the SHoT studies has expanded over time, and this study is based on SHoT 2018, which was a collaboration between the Norwegian Institute of Public Health (NIPH) and the three largest student welfare organisations in Norway. All Norwegian fulltime students aged 18–35 years taking higher education (both in Norway and abroad) were invited for participation (N = 162,512). Totally, 50,054 students (31% response) completed the electronic questionnaire. SHoT 2018 includes self-reported information on mental and physical health, quality of life, health related behaviours, medication use, study related information, demographics, and background factors (33). The sample of this study includes responses from 34,437 female and 15,399 male students, excluding 218 students reporting transgender sex, giving a final sample of 49,836 higher education students. The response rate among females and males was 36.9 and 22.8%, respectively.
Ethics
The SHoT 2018 study was approved by the Regional Committee for Medical and Health Research Ethics in Western Norway (reference number 2017/1176). Participation was voluntary, and electronic informed consent was obtained from all participants (32).

Measurements
Psychological Distress
Psychological distress symptoms were assessed using The Hopkins Symptoms Checklist (HSCL-25). HSCL-25 is a widely used, validated screening tool used to assess symptoms of anxiety and depression. The scale consists of 10 items for anxiety and 15 items for depression, each scored on a Likert scale (1-4). The symptoms of anxiety and depression were assessed for the period of the past 2 weeks. HSCL-25 has psychometric properties suitable for detecting symptoms of anxiety and/or depression in different population settings such as the general population (35), primary care outpatients (36), and refugee patients with different cultural backgrounds (37). To indicate clinically relevant psychological distress symptom load, a cut-off at 1.75 was proposed in the original version (34) and used in several studies (11, 36). Additionally, a more conservative cut-off of ≥2.0 has been used to indicate moderate to severe psychological distress symptoms (6, 32). This study uses ≥2.0 cut-offs to describe the study population and in the logistic regression analyses.

Psychotropic Drug Use
The use of drugs was assessed by asking if the participants had used either of the following medicines at least once a week during the last 4 weeks: antidepressants, anxiolytics/tranquillisers, or hypnotics. The use of prescription analgesics, non-prescription analgesics, anti-allergic agents, antibacterial agents, anti-asthmatic agents, and any other medicine was also self-reported in the SHoT 2018 questionnaire and was combined and assessed as “any medicine” in our analysis. Response options were: Daily; every week, but not daily; less than every week; not used last 4 weeks. For antidepressants and “any medicine,” the responses were analysed as: Daily use; Used last 4 weeks, but less than daily (combining every week, but not daily and less than every week); and Not used last 4 weeks. For anxiolytics/tranquillisers, and hypnotics, the response were analysed as: Used last 4 weeks; Not used last 4 weeks. Regarding performance-enhancing drugs, the participants were asked: During your study period, have you ever used drugs that increase your ability to concentrate, your alertness, increase your energy, or to calm down before exams/presentations? The possible responses were yes or no. If answering yes, the following question was: Which drug(s) have you used to increase your ability to concentrate, your alertness, increase your energy, or to calm down before exams/presentations? The questionnaire included a list of possible drug names, for which participants could tick one or more options: amphetamine; methylphenidate; modafinil; paracet (acetaminophen)/ibuprofen etc; other. The number of study participants ticking the stimulants amphetamine, methylphenidate, and modafinil, were summarised.

Statistical Analysis
Difference in self-reported psychological distress was examined by comparing total HSCL-25 score [mean (95% confidence interval (CI))] as well as proportions (95% CI) scoring above the cut-offs between the groups in relation to health-related factors, medication use, lifestyle, background information, sociodemographic characteristics, and clinical measurements. Generalised linear models with a log link function and identity link function were used to calculate rate ratio (RR) and rate difference (RD) between psychotropic drug use and self-reported psychological distress, respectively. The models were adjusted for age, age squared, financial distress, living alone, self-rated health, loneliness, marital status, and foreign-born variables. We obtained robust standard errors for the parameter estimates. RR and RD are reported with 95 per cent confidence intervals (95% CI). Stata v.16 was used for all data management and statistical analysis (40).

RESULTS
Table 1 shows the demographic and health characteristics of the university student population, including psychological distress symptom load, gender stratified. Two thirds of students were female, and the mean age was 23.1 and 23.5 years among women and men, respectively. There were 7,661 foreign-born study participants, 14.9% of the females and 16.5% of males. Half of the study participants were single, and 19.3% lived alone. Nearly 17% of the females and 15% of the males felt lonely often or very often. Furthermore, 58.9% of the women, and 67.7% of the men reported financial distress. Further, 23.1% of the females and 14.9% of the males reported “poor” or “not so good” global health. The prevalence of moderate to severe symptom load of anxiety and depression (HSCL-25 ≥ 2.00) was 33.6% in female and 16.8% and male students.

Table 2 describes the self-reported psychotropic drug use. Female students had a higher prevalence of daily antidepressants usage (4%) than male students (2.3%). The female students' usage
of anxiolytics/tranquillisers and hypnotics the last 4 weeks (4.6 and 7.7%, respectively) were higher than among males (3.2 and 5.2%, respectively). The prevalence of performance-enhancing drug use was higher among male than female students (6.5 vs. 4.8%). Totally 988 (2%) students reported to have used amphetamine, methylphenidate, and/or modafinil during their studies. The percent of missing data on psychotropic drug use variables varied between 13.2 and 14.2.

Table 3 shows the adjusted associations between psychological distress symptoms and use of psychotropics. The risk of daily use of antidepressants was more than 2-fold increased among both genders, with RR 2.36 and 2.09, and RD 4 and 3.4 percentage points (pp) for males and females, respectively. Psychological distress increased the risk of using anxiolytics/tranquillisers, with a RR of 2.8 and 2.6 in male and female students, respectively, and an absolute RD of 6.5 and 5.3 pp in males and females, respectively. Furthermore, when reporting psychological distress, the risk of daily use of hypnotics increased with approximately a 2-fold in females, and 2.2 times in males.

**DISCUSSION**

**Main Findings**

This large, nation-wide study of more than 48,000 Norwegian students from all faculties and universities, provide information on psychotropic drug usage among students in relation to psychological distress, previously scarcely described in the literature. The prevalence of psychotropic drug use was mainly in line with results of previous studies (20, 21). Both female and male students typically used antidepressants daily, while anxiolytics/tranquillisers and hypnotics were used more sporadically, which is according to clinical guidelines (41, 42). Female students were more frequent users of antidepressants than males (daily use in 4 vs. 2%), anxiolytics/tranquilisers (5 vs. 3% last month) and hypnotics (8 vs. 5% last month), while the opposite was reported for stimulants (5 vs. 7%). Overall, these results align with previous research on gender differences in mental health and help-seeking (8, 9). In contrast, within cases (HSCL cut-off at ≥ 2.0) patterns of psychotropic drug use were
Patterns of Psychotropic Drug Use in Female and Male Students

This study describes a student population where approximately one quarter of the respondents showed a moderate to severe symptom load of anxiety and depression, and a previous study has concluded that both the level and increasing prevalence of psychological distress among Norwegian students is worrying (11). We found that the prevalence of psychotropic drug use varied between genders and classes of psychotropic medications. Similar results regarding a general increase, and gender and psychotropic drug class patterns have also been reported among children and adolescents (12–16). In particular, an increased use of hypnotics and antidepressants in adolescents has received attention (12, 13, 16). Of note, the increased hypnotics usage can largely be attributed to the increased use of melatonin (12, 13, 15), which until 2020 was a prescription drug in Norway. Previous studies have emphasised that sleep problems among students are prevalent and increasing (33), and insomnia prevalence is considerably higher in university students compared to the general population (43). Therefore, continued monitoring of hypnotics use among students is warranted, with special focus on melatonin use and effects in this population.

This study describes a prevalence of performance-enhancing drug use, including stimulants the last month, of 4.8 and 6.5% among females and male students, respectively. We cannot conclude whether these drugs were illicit or misused drugs. However, a previous study described that a substantial proportion of the Norwegian students have tried illicit drugs, and males more so than females (28). A meta-analysis described the misuse of stimulant medications among students as a prevalent and growing problem. Also, being male was associated with misuse of stimulants, and the most common source of stimulants access were fellow students with prescriptions (24). McCabe et al. found that the trend of increased use of prescribed psychotropics among students was related to the increased non-medical use of these medications (20). Altogether, these results confirm the need of continued monitoring prevalence of psychotropic drug use among students and highlight the need of safeguarding the correct use of psychotropics, in addition to ensuring patient safety strategies in this population. For example, health services with interprofessional healthcare teams should be accessible to all students, being available and competent of giving advice and counselling of proper psychotropic drug use. Educational interventions on psychotropic drug use targeted at students, student counsellors, and other relevant university staff could be useful as preventive measures.

Psychotropic Drug Use in Male and Female Students With High (HSCL ≥ 2.0) Symptom Level

Mental health help seeking is more common in female compared to male students (6), and previous studies of young adults with mental health conditions have confirmed that females are more likely to receive treatment than males (3, 18). Brijnath et al. described an increasing trend of general practitioners’ prescription of psychotropics to young people with mental health conditions from 2009 to 2014, and females had a higher incident rate for prescription than males (IRR 1.15, 95% CI 1.08–1.22) (18). In the study by Bruffaerts et al., the self-reported receipt of mental health treatment was examined among nearly
**TABLE 3 | Adjusted\(^a\) associations between psychological distress and daily psychotropic drug use, given by risk ratio (RR) and risk difference (RD) with 95 per cent confidence interval (95% CI).**

| Relative and absolute differences\(^a\) | RR   | 95% CI        | RD    | 95% CI        |
|----------------------------------------|------|---------------|-------|---------------|
| **Females and Males**                  |      |               |       |               |
| Antidepressants                        |      |               |       |               |
| HSCL ≥ 2.0                             | 2.16 | (1.91–2.45)   | 0.036 | (0.030–0.042) |
| Anxiolytics/tranquillisers             |      |               |       |               |
| HSCL ≥ 2.0                             | 2.61 | (2.34–2.92)   | 0.055 | (0.049–0.062) |
| Hypnotics                              |      |               |       |               |
| HSCL ≥ 2.0                             | 2.03 | (1.87–2.21)   | 0.068 | (0.060–0.076) |
| Performance-enhancing drugs            |      |               |       |               |
| HSCL ≥ 2.0                             | 1.90 | (1.72–2.09)   | 0.039 | (0.033–0.045) |
| Any medicine                           |      |               |       |               |
| HSCL ≥ 2.0                             | 1.00 | (0.96–1.05)   | 0.003 | (−0.008 to 0.014) |
| **Females**                            |      |               |       |               |
| Antidepressants                        |      |               |       |               |
| HSCL ≥ 2.0                             | 2.09 | (1.82–2.40)   | 0.034 | (0.028–0.040) |
| Anxiolytics/tranquillisers             |      |               |       |               |
| HSCL ≥ 2.0                             | 2.60 | (2.28–2.96)   | 0.063 | (0.048–0.060) |
| Hypnotics                              |      |               |       |               |
| HSCL ≥ 2.0                             | 1.99 | (1.82–2.19)   | 0.066 | (0.057–0.075) |
| Performance-enhancing drugs            |      |               |       |               |
| HSCL ≥ 2.0                             | 1.92 | (1.70–2.17)   | 0.034 | (0.028–0.041) |
| Any medicine                           |      |               |       |               |
| HSCL ≥ 2.0                             | 1.00 | (0.96–1.05)   | 0.001 | (−0.012 to 0.013) |
| **Males**                              |      |               |       |               |
| Antidepressants                        |      |               |       |               |
| HSCL ≥ 2.0                             | 2.36 | (1.78–3.13)   | 0.040 | (0.028–0.053) |
| Anxiolytics/tranquillisers             |      |               |       |               |
| HSCL ≥ 2.0                             | 2.81 | (2.23–3.55)   | 0.065 | (0.050–0.080) |
| Hypnotics                              |      |               |       |               |
| HSCL ≥ 2.0                             | 2.21 | (1.84–2.66)   | 0.076 | (0.057–0.094) |
| Performance-enhancing drugs            |      |               |       |               |
| HSCL ≥ 2.0                             | 1.87 | (1.58–2.21)   | 0.066 | (0.039–0.073) |
| Any medicine                           |      |               |       |               |
| HSCL ≥ 2.0                             | 1.06 | (0.90–1.24)   | 0.006 | (−0.013 to 0.025) |

\(^a\) HSCL < 2.0 was used as reference in all analyses, with RR = 1 and RD = 0. Adjusted for age, age squared, financial distress, living alone, self-rated health, loneliness, marital status, and foreign-born.

\(^b\) Also adjusted for sex.

14,000 first year students from 19 colleges in eight countries world-wide. They reported on sociodemographic predictors of treatment, where being female was an independent predictor of both lifetime and 12-month treatment (3). In our study, however, the use of psychotropic drugs among female and male students with psychological distress was more or less identical across all psychotropic drug classes.

Evidently, help-seeking involves opportunities for diagnosis and treatment, and implies positive association to medication usage. However, several factors are known to affect the use of mental healthcare among young adults, e.g., type and severity of mental health problem, stigma, mental health literacy, socioeconomic position, healthcare organisation and infrastructure (8, 44), that would subsequently influence possibilities for detection of treatment needs. Furthermore, help-seeking among students is generally low, varies between university and college campuses, and across student characteristics (6, 45, 46). Accordingly, a high unmet need for treatment of mental disorders among students has been recognised (3, 22). Further research regarding psychotropic drug use among students with mental health problems is warranted, and should involve longitudinal studies, and examine gender differences of causal and treatment factors, as well as medication safety issues in this population. Furthermore, systematic strategies to increase detection of need for mental health treatment among university students is of great importance, and might need several interventions at different levels, including an interdisciplinary approach. Generally, health authorities and
universities need to focus on student mental health, to reduce psychological distress among students, and encourage students to seek help when needed.

**Strengths and Limitations**

The main strength of this study is the large, national sample of university students.

Limitations include the modest response rate (31%) and the potential selection bias regarding the prevalence measures and associations (32). Furthermore, self-reported anxiety and depression symptoms were assessed using the HSCL-25 with a conventional cut-off at ≥2.0. Although commonly used, and often the only feasible method in large scale studies, self-reported symptom levels do not compare directly to diagnostic categories of these conditions. Similarly, the self-reported use of medication has obvious limitations compared to register data, and the SHoT 2018 survey did not include information on whether the psychotropics were obtained through a prescription.

The self-reported psychotropic drug usage was reported as daily or monthly prevalence, and are thereby not directly comparable to past-year prevalence commonly used in other pharmacoepidemiologic studies.

**CONCLUSION**

Our study suggests similar prevalence and gender patterns of intake of the most common psychotropic drug classes among Norwegian students, compared to European and US studies (20, 21). The vast majority of antidepressant users took their drugs daily, according to the prescription guidelines (41). In contrast, anxiolytics and sedatives were taken more infrequently, which is also recommended. Although mental health help seeking is much more common in female compared to male students (6, 19), the patterns of drug use in female and male students were more or less identical across all psychotropic drug classes in our study.

**REFERENCES**

1. Auerbach RP, Mortier P, Bruffaerts R, Alonso J, Benjet C, Cuipers P, et al. WHO world mental health surveys international college student project: prevalence and distribution of mental disorders. *J Abnorm Psychol.* (2018) 127:623–38. doi: 10.1037/abn0000362
2. Alonso J, Mortier P, Auerbach RP, Bruffaerts R, Vilagut G, Cuipers P, et al. Severe role impairment associated with mental disorders: results of the WHO world mental health surveys international college student project. *Depress Anxiety.* (2018) 35:802–14. doi: 10.1002/da.22778
3. Bruffaerts R, Mortier P, Kiekkens G, Auerbach RP, Cuipers P, Demyttenaere K, et al. Mental health problems in college freshmen: prevalence and academic functioning. *J Affect Disord.* (2018) 225:97–103. doi: 10.1016/j.jad.2017.07.044
4. Drapeau A, Marchand A, Beaulieu-Prévost D. Epidemiology of psychological distress. In: LaBate L, editor. *Mental Illness-Understanding, Prediction and Control.* Rijeka: INTECH (2012). p. 105–34. doi: 10.5772/30872
5. Sharp J, Theiler S. A review of psychological distress among university students: pervasiveness, implications and potential points of intervention. *Int J Adv Counsel.* (2018) 40:193–212. doi: 10.1007/s10447-018-9321-7
6. Grostan K, Sund ER, Bjerketan O. Mental health, academic self-efficacy and study progress among college students - the SHoT study, Norway. *Front Psychol.* (2019) 10:45. doi: 10.3389/fpsyg.2019.00045
7. Tang F, Byrne M, Qin P. Psychological distress and risk for suicidal behavior among university students in contemporary China. *J Affect Disord.* (2018) 228:101–8. doi: 10.1016/j.jad.2017.12.005
8. Kovess-Masfety V, Boyd A, Van De Velde S, De Graaf R, Vilagut G, Haro JM, et al. Are there gender differences in service use for mental disorders across countries in the European Union? Results from the EU-World Mental Health survey. *J Epidemiol Community Health.* (2014) 68:649–56. doi: 10.1136/jech-2013-202962
9. Boyd A, Van De Velde S, Pivette M, Ten Have M, Florescu S, O’Neill S, et al. Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study. *Eur Psychiatry.* (2015) 30:778–88. doi: 10.1016/j.eurpsy.2015.05.001
10. Gunnell D, Kidger J, Elvidge H. Adolescent mental health in crisis. *BMJ.* (2018) 361:k2608. doi: 10.1136/bmj.k2608
11. Knapsdøl M, Sivertsen B, Knudsen AK, Smith ORF, Aasø LE, Lonning KJ, et al. Trends in self-reported psychological distress among college and university students from 2010 to 2018. *Psychol Med.* (2019) 51:470–8. doi: 10.1017/S0033291719003350
12. Hartz I, Furu K, Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: a nationwide prescription database study. *Scand J Public Health.* (2012) 40:704–11. doi: 10.1177/1403494812464446
13. Hartz I, Skurtveit S, Steffenak AK, Karlstad O, Handal M. Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. *BMC Psychiatry.* (2016) 16:12. doi: 10.1186/s12888-016-0716-x

**DATA AVAILABILITY STATEMENT**

The datasets for this article are not publicly available because of privacy regulations from the Norwegian Regional Committees for Medical and Health Research Ethics (REC). Requests to access the datasets should be directed to BS (borge.sivertsen@fhi.no). Guidelines for access to SHoT data are found at https://www.fhi.no/en/more/access-to-data. Approval from REC (https://helseforskning.etikkom.no) is a pre-requirement.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Regional Committee for Medical and Health Research Ethics in Western Norway (reference number 2017/1176). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

IB and ES conducted analyses. IB and HS drafted the manuscript. All authors contributed to conception of the study, interpretation of the findings, and critical revisions of the manuscript for intellectual content and have approved the manuscript for submission.

**FUNDING**

SHoT2018 has received funding from the Norwegian Ministry of Education and Research (2017) and the Norwegian Ministry of Health and Care Services (2016).

**ACKNOWLEDGMENTS**

We wish to thank all participating students.
14. Häldénarson Ö, Zoeiga H, Aagaard L, Bernardo M, Brandt L, Furst,É, et al. International trends in antipsychotic use: a study in 16 countries, 2005-2014. *Eur Neuropsychopharmacol.* (2017) 27:1064–76. doi: 10.1016/j.euroepro.2017.07.001

15. Rasmussen L, Bilgen N, Thomsen Ernst M, Abit Boysen S, Pottage Á. Use of psychotropic drugs among children and adolescents with autism spectrum disorders in Denmark: a nationwide drug utilization study. *J Clin Med.* (2018) 7:339. doi: 10.3390/jcm7030339

16. Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Butler D, et al. Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: a population-based cohort study. *PLoS Med.* (2020) 17:e1003215. doi: 10.1371/journal.pmed.1003215

17. Norwegian Prescription Database (2021). Available online at: http://www. reseret Arrest.no/Prevalens.aspx (accessed February 15, 2021).

18. Brijnath B, Xia T, Turner L, Mazza D. Trends in GP prescribing of psychotropic medications among young patients aged 16-24 years: a case study analysis. *BMC Psychiatry.* (2017) 17:214. doi: 10.1186/s12888-017-1375-2

19. Ruud N, Løvseth LT, Isaksen Ro K, Tyssen R. Comparing mental distress and help-seeking among first-year medical students in Norway: results of two cross-sectional surveys 20 years apart. *BMJ Open.* (2020) 10:e036968. doi: 10.1136/bmjopen-2020-036968

20. Mccabe SE, West BT, Teter CJ, Boyd CJ. Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2002 to 2013: connecting the dots. *Addict Behav.* (2014) 39:1176–182. doi: 10.1016/j.addbeh.2014.03.008

21. Fond G, Bourbon A, Lançon C, Bourkeckine M, Micoulaud-Franchi JA, Auquier P, et al. Psychiatric and psychological follow-up of undergraduate and postgraduate medical students: prevalence and associated factors. Results from the national BOURBON study. *Psychiatry Res.* (2019) 272:425–30. doi: 10.1016/j.psychres.2018.12.174

22. Auerbach RP, Alonso J, Axinn WG, Cuijpers P, Ebert DD, Green JG, et al. Incidence and prevalence of mental disorder among college students: a systematic review and meta-analysis. *Int J Drug Policy.* (2014) 25:250–7. doi: 10.1016/j.addbeh.2016.08.023

23. Moore DR, Burgard DA, Larson RG, Ferm M. Psychostimulant use among college students during periods of high and low stress: an interdisciplinary approach utilizing both self-report and unobtrusive chemical sample data. *Addict Behav.* (2014) 39:987–93. doi: 10.1016/j.addbeh.2014.01.021

24. Munro RA, Weyandt LL, Marraccini ME, Oster DR. The relationship between nonmedical use of prescription stimulants, executive functioning and academic outcomes. *Addict Behav.* (2016) 65:250–7. doi: 10.1016/j.addbeh.2016.08.023

25. Sivertsen B, Rakil H, Munkvik E, Lønning KJ. Cohort profile: the SHOt-study, a national health and well-being survey of Norwegian university students. *BMJ Open.* (2019) 9.e025200. doi: 10.1136/bmjopen-2018-025200

26. Heradstveit O, Skogen JC, Edland-Gryt M, Hesse M, Vallentin-Holbeck L, Auerbach RP, et al. Executive functioning and academic outcomes. *BMC Psychiatry.* (2014) 15:535. doi: 10.1186/1471-244X-15-535

27. Papazisis G, Tsakiridis I, Pourzitaki C, Apostolidou E, Spachos D, Kouvelas A. Use of psychotropic drugs among children and adolescents with autism spectrum disorders in Denmark: a nationwide drug utilization study. *J Clin Med.* (2018) 7:339. doi: 10.3390/jcm7030339

28. Heradstveit O, Skogen JC, Edland-Gryt M, Hesse M, Vallentin-Holbeck L, Auerbach RP, et al. Executive functioning and academic outcomes. *BMC Psychiatry.* (2014) 15:535. doi: 10.1186/1471-244X-15-535

29. Sivertsen B, Vedaa O, Harvey AG, Gliozier N, Pallesen S, Aaro LE, et al. Sleep patterns and insomnia in young adults: a national survey of Norwegian university students. *J Sleep Res.* (2019) 28:e12790. doi: 10.1111/jsr.12790

30. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covil L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. *Behav Sci.* (1974) 19:1–15. doi: 10.1002/bs.3830190102

31. Glaesner H, Braehler E, Grande G, Hinz A, Petermann F, Romppel M. The German version of the hopskins symptomcheck-list (HSCL-25) – factorial structure, psychometric properties, population-based norms. *Compr Psychiatry.* (2014) 55:396–403. doi: 10.1016/j.comppsych.2013.08.020

32. Nabbe P, Le Reste JY, Guillou-Landreat M, Gatinneau F, Le Floch B, Montier T, et al. The French version of the HSCL-25 has now been validated for use in primary care. *PLoS One.* (2019) 14:e0214804. doi: 10.1371/journal.pone.0214804

33. Wind TR, Van Der Aa N, Knipscheer J, De La Rie S. The assessment of psychopathology among traumatized refugees: measurement invariance of the Harvard Trauma Questionnaire and the Hopkins Symptom Checklist-25 across five linguistic groups. *Eur J Psychotraumatol.* (2017) 8:1321357. doi: 10.1002/20080198.2017.1321357

34. Bae T, Hysing M, Lennng KJ, Sivertsen B. Financial difficulties and student health: results from a National Cross-Sectional Survey of Norwegian college and university students. *Mental Health Prevent.* (2021) 21:e200196. doi: 10.1016/j.mhp.2020.200196

35. Hysing M, Petrie KJ, Bae T, Lennng KJ, Sivertsen B. Only the lonely: a study of loneliness among university students in Norway. *Clin Psychol Europe.* (2020) 2:1–16. doi: 10.32872/cpe.v2i1.2781

36. Statcorp. *Statas Statistical Software: Release 16.* College Station, TX: StataCorp LLC (2019).

37. National Institute for Health and Care Excellence. *Depression in Adults: Recognition and Management. NICE Clinical Guideline (CG90).* (2009). Available online at: https://www.nice.org.uk/guidance/cg90 (accessed March 20, 2021).

38. National Institute for Health and Care Excellence. *Generalised Anxiety Disorder and Panic Disorder in Adults: Management (CG113).* (2019). Available online at: https://www.nice.org.uk/guidance/cg113 (accessed March 20, 2021).

39. Jiang XL, Zheng XY, Yang J, Ye CP, Chen YY, Zhang ZG, et al. A systematic review of studies on the prevalence of insomnia in university students. *Public Health.* (2015) 129:1579–84. doi: 10.1016/j.puhe.2015.07.030

40. Gulliver A, Griffiths KM, Christensen H. Perceived barriers and facilitators to mental health help-seeking in young people: a systematic review. *BMC Psychiatry.* (2010) 10:113. doi: 10.1186/1471-244X-10-113

41. Eisenberg D, Hunt J, Speer N, Zivin K. Mental health service utilization among college students in the United States. *J Nerv Ment Dis.* (2011) 199:301–8. doi: 10.1097/NMD.0b013e3182175123

42. Mclafferty M, Lapsley CR, Ennis E, Armour C, Murphy S, Bunting BP, et al. Mental health, behavioural problems and treatment seeking among students commencing university in Northern Ireland. *PLoS ONE.* (2017) 12:e0188785. doi: 10.1371/journal.pone.0188785

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Bojanić, Sund, Bjerkeset, Sivertsen and Sletvold. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.